Axovant Sciences Ltd. (NYSE: AXON) reported Q1 EPS of ($0.35).

"We remain on track to commence the confirmatory phase 3 study for RVT-101 in Alzheimer's disease in the fourth quarter of 2015," stated Vivek Ramaswamy, Chief Executive Officer of Axovant Sciences, Inc. "We look forward to providing additional updates later this year regarding our progress towards building a dementia solutions company."

Leadership Update

Axovant is pleased to announce the appointment of Gregory Weinhoff, MD, MBA as the Chief Financial Officer of Axovant Sciences, Inc. and the Principal Financial Officer of Axovant Sciences Ltd. Dr. Weinhoff succeeds Alan S. Roemer, who will continue in his role as Senior Vice President, Finance & Operations at Roivant Sciences, Inc., an affiliate of Axovant.

"Dr. Weinhoff brings extensive financial, scientific and strategic experience to Axovant," commented Berndt Modig, director and Chair of the Audit Committee of Axovant Sciences Ltd. "As a newly public company with a large Phase 3 program getting underway, Axovant will benefit greatly from Dr. Weinhoff's broad industry expertise. We welcome Dr. Weinhoff and also thank Mr. Roemer for his significant contributions to Axovant."

Dr. Weinhoff has more than twenty years of experience in finance and operations in the healthcare industry, including as a venture capital investor and board member with audit committee experience. He was the founding Chief Executive Officer of Amicus Therapeutics, Inc. and later served as a member of the audit committee of Amicus' Board of Directors. Dr. Weinhoff joins Axovant from his role as a partner at CHL Medical Partners, a firm focused on investments into early-stage companies across therapeutics, diagnostics, medical devices and healthcare services sectors. Dr. Weinhoff was the founding President of VaxInnate Corporation and the President of Resolvyx Pharmaceuticals, Inc. He also served in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co. Dr. Weinhoff received his M.D. from Harvard Medical School, his M.B.A. (Baker Scholar) from Harvard Business School, and his A.B. in Economics (magna cum laude) from Harvard College.

For earnings history and earnings-related data on Axovant Sciences Ltd. (AXON) click here.